< Previous30 Food & Drink Internationalwww.fdiforum.netCONTAINERS & PALLETSThose considering containers andpallets often have to deal with twoseemingly contradictory aims. Strengthand security are absolutely key withcustomer and employee safety an absolutetop priority. However convenience andefficiency is also a major driver ofinnovation. Increasingly the palletsthemselves are often on display in storesso have to allow consumers the ability toaccess the products, while lightweightconstruction also ensures they are easierto transport and use less energy.The latest containers and pallets canmeet all requirements, however, with anincrease in quality across the board. Thatwas the view of the European PalletAssociation when they held their firstpallet symposium in Spain earlier thisyear. Around sixty Spanish logisticsexperts, pallet manufacturers and repairorganisations, as well as usersfrom trade and industry,discussed current and futuredevelopments, including theadvantages of the openEuro pallet exchange pooland the sustainability of thewooden cargo carrier, aswell as the independentquality controls and themodern applicationpossibilities of palletsequipped with RFIDtechnology.RFID working with palletscould well make adifference to the supplychain with companies nowoffering plastic pallet poolingas standard to its customers.PLS, a subsidiary of BibbyDistribution, for example, saysthat by adopting this method of assettracking, customers can achieve greatervisibility of pallets as they move throughthe supply chain. This results in increasedproductivity, better inventory managementand, ultimately, reduced costs.Each pallet is fitted with two passiveRFID tags to ensure maximum readability.Traceability is also improved as eachpallet is also sequentially numbered andbar coded. The use of EPC compliant tagsenables the pallet to be integrated into thecustomer’s supply chain and RFIDsystems. This generates additionalefficiencies, such as assisting in producttracking and automatic inventory updateswithin the customer’s supply chain, aswell as when pallets reach the endcustomer. Although there is additionalexpense with the introduction of RFID,the ability to locate pallets that couldpreviously get lost should lead to savingsin the long run – and costs will clearlycome down as the technology becomescommonplace.The RFID technology can usually befound on plastic pallets which areenjoying increased popularity. Plasticpallets can offer benefits in terms ofhygiene – regular cleaning can ensure thatbacteria or mould can be easily removed –as well as proving more robust and easierto colour code. This isn’t to say thatwooden pallets don’t have their ownadvantages. At a time whenenvironmental aspects are a top priorityfor many they have a much smaller carbonfootprint and are biodegradable at the endof their life, and they continue to beavailable at a lower price. Individualcompanies should be able to decide on thepallets that are most suitable for theirneeds.Palletising itself brings with itvarious challenges and theautomation of this process iscontinuing apace. Forexample, robots from ABBhave helped systemsintegrator RM Group to turna new idea for a mobilepackaging system into aworking reality. Housed in45ft articulated trailers, RMGroup’s mobile packagingplant uses ABB’s IRB 6640and IRB 460 robots as part ofa system designed to providecustomers with a versatile,efficient and easilytransportable way ofbagging products at source.The robots have aGoplasticboxes.com has introduceda new colourful transport dolly to itsrange of box accessories32 Convenience withconfidenceThe latest containers and pallets offer efficiency and convenience, without compromising onsafety and security30-32:Layout 1 22/9/14 09:28 Page 1Food & Drink International 31www.fdiforum.netCONTAINERS & PALLETSThe integration of ABBRobots has allowedfor fast, automatedpalletising ofpackaged products30-32:Layout 1 22/9/14 09:28 Page 232 Food & Drink Internationalwww.fdiforum.netCONTAINERS & PALLETSpayload of up to 235kg, enabling it tohandle extremely heavy materials, while itis particularly suitable for restricted spacessuch as small factory floors. Running thesecond generation of ABB’s TrueMoveand QuickMove software, the robot offersgreater movement accuracy, with less timeneeded for programming. As well as improved efficiency, thesystem also helps users to realiseoperational and environmentalimprovements. By eliminatingtransportation between product sourceand packing location, the system can alsohelp to reduce Co2 emissions, with noneed to ferry products to and from off-sitebagging facilities.Llewelyn Rees, Managing Director ofRM Group, says, “The integration ofABB Robots allows for fast, automatedpalletising of the packaged products. TheIRB 6640 robots have been a completesuccess for RM Group, coping with thehigh demands and withstandingthousands of miles of haulage andcontinual labour, while the IRB 460 helpsto deliver fast packaging output speedswith combined precision in palletising.”One major issue while using containersand pallets is the convenience whiletransporting them. The potential forhealth and safety breaches can be verygreat and a number of methods are nowavailable to help transport the items in asecure and safe manner.Goplasticboxes.com, for example, hasintroduced a new colourful transport dollyto its range of box accessories. Designed to facilitate the safe and easymovement of stacked crates, the dolliesare lightweight, hygienic and suitable foruse in cold stores, clean rooms and retailspace. This doesn’t come at the expenseof strength, however, and the dolly ismanufactured from virgin, fully recyclableABS which is recognised for its toughnessand impact-resistance.The dolly’s wide-set base measures607mm x 407mm and lips around theperimeter ensure secure stacking for boxesof various sizes from shallow trays totaller-sided crates. A twist and turnfeature means it can be turned andstacked at ninety degrees in stacks up to25 dollys high when empty. The dolly canalso tolerate loads of up to 300kg, whichis 50kg more than other dollies of asimilar size, and is supported by fourrevolving run-silent castors.The other challenge is ensuring thewarehouse is safe and secure whiletransporting the pallets, and a range ofhigh quality trucks is ensuring this is thecase. For example, the Tergo URS turrettruck is augmenting the Atlet productfamily from UniCarriers. The new forklifthas the smallest turning circle in its classand can operate easily and safely inwarehouses with particularly narrowaisles. Its ergonomically optimised chassis,along with an individually adjustable seatheight, back rest and positioning ofcontrols, provides a working environmentthat guarantees maximum user comfort.With more and more companies awareof the importance of keeping workers safewithout compromising their health, this isbecoming increasingly valuable forbusinesses. The forks, which can beturned through 180 degrees, allowconvenient placement of the goods onboth sides of an aisle. In narrow aisles,the Tergo URS is steered by means ofguide rails or inductive guidance, allowingthe driver to concentrate fully on thestacking process. Outside the aisles, it canbe operated as a free-range truck.As customers look to improve theirefficiency, the latest developments incontainers and pallets can ensureexceptional savings are made – whileensuring products remain secure and safe.Our complete truck range at your serviceYou can call us for further information on 01844 215501 or email sales@atlet.co.ukwww.atlet.co.ukOrganisations such as RTITBensure safety and security acrossthe distribution supply chain30-32:Layout 1 22/9/14 09:28 Page 3Your guide to the pharmaceutical world PharmaBUSINESS INTERNATIONALThe total packageFrom development to dispensingThe total packageFrom development to dispensingwww.pbiforum.netPHOTO: SHUTTERSTOCK.COM/LIGHTSPRING33:Layout 1 22/9/14 09:29 Page 1New managing directorappointed at Clondalkin GroupClondalkin Group hasappointed Tomasz Krogulskias Managing Director of itsleading Pharma andHealthcare manufacturingfacility in Lublin, Poland. Tomasz will be responsiblefor the overall management ofthe facility and will continuewith the implementation of the plant’s continuous improvement programme. He will build on the successful ongoingwork to provide customers with the very best products and service levels. He brings with him over twenty years of experience in the packaging sector, working for some of the industry’sbiggest names, and as a consultant in China and India. His practical experience is supported by education at WarsawUniversity of Technology (Printing) and Warsaw School of Economics.Tomasz says, “Clondalkin as an international company will give me the opportunity to work alongside many differentpeople. I’m committed to delivering a world class standard here in Lublin to meet both the needs of our customers and the long-term ambitions of the Group.”34Pharma Business International www.pbiforum.netWelcomeSanner introduces AdPack desiccant pillow pack family Sanner GmbH is expanding its portfolio with the new AdPack desiccant pillow packs – an efficient,economical and safe solution for the protection of moisture-sensitive pharmaceuticals such as tablets andcapsules inside the packaging. Sanner CEO Holger Frank says, “With the AdPack desiccant pillow packs, we have developed a newdrop-in solution for moisture protection inside the packaging. This offers our customers a cost-efficientsolution that unites all the advantages of GMP-compliant production, professional risk management, 100%traceability and outstanding Sanner quality.”The pillow packs are available as single strips or on reel, and are made of industry-leading, extremelydurable, and tear-resistant Tyvek material. AdPack is highly permeable and ensures long-term adsorption ofmoisture and odours. Due to the flexible non-dusting, lint-free Tyvek material, the packagedpharmaceuticals remain intact at all times. The low-profile AdPack desiccant pillow packs take up littlespace within a package and their distinct shape eliminates potential confusion with capsules or tablets, andprevents accidental ingestion.From development todispensingWelcome to this special supplement from Pharma BusinessInternational. As the sister publication of Food & DrinkInternational, it offers the same mix of the latest news, incisiveopinion and valuable editorial covering the whole of thepharmaceuticals sector – from development to dispensing. Asmany food and drink companies are looking towards the sectoras a potential growth market, Pharma Business Internationalis your complete guide to entering this exciting area.If you like what you see over the next fewpages, visit www.pbiforum.net for moreinformation and to check out the latestissue!“Jewel in the crown” science parkreceives £4.6 million birthdaygiftDiscovery Park, which is celebrating its second anniversary, has received abirthday present of a £4.6 million grant from the South East Local EnterprisePartnership to support further investment in roads and services.Discovery Park was created in July 2012, after pharmaceutical giant Pfizerannounced it would be reducing its activities at the 220-acre site in Sandwich,Kent. Private consortium Discovery Park bought the site and, since then, thescience and technology-led park has created more than 1600 jobs, including sixhundred still employed by Pfizer, and attracted nearly a hundred businesses. It ison course to achieve three thousand jobs by 2017.Paul Barber, managing director of Discovery Park, says, “What we’ve achievedso far is just the beginning of the journey. We don’t want to be a successfulscience and technology-led business park in East Kent, we want it to be one ofthe best in the world.”34-37:Layout 1 22/9/14 09:42 Page 1Pharma Business International 35www.pbiforum.netLatest newsSpecialist supporton hand forHorizon 2020applicationsUK company Boyds, which workswith organisations specialising in thedevelopment of early stage drugs andmedical devices, is channelling itspharmaceutical and biotechnologyexpertise to support Life Sciencecompanies applying for Horizon 2020grant funding.Horizon 2020 is the EuropeanUnion’s biggest ever Research andInnovation programme. It has nearly€80 billion of funding available overthe next seven years with the aim ofstrengthening the EU’s global positionin research, innovation andtechnology.Boyds has extensive experience ofdeveloping medicinal products andbringing them to market, alongside along and proven track record ofsuccessfully securing funding foracademic institutions, organisationsand companies. Founder and CEOProfessor Alan Boyd says, “We havesuccessfully worked with partneringgroups from industry and academiato help obtain funding from numerousEuropean sources and this expertisehas armed us with the knowledge andskills to give all funding applicationspurpose and maximum commercialpotential.”Alizé Pharma raises €5 million from InnoBioAlizé Pharma SAS has closed a new financing round of €5million. The funds will be used to continue the clinical programfor AZP-531, including the set-up and completion of a Phase IItrial in hyperphagia associated with Prader-Willi syndrome and aPhase Ib trial in type 2 diabetes.The French public investment bank Bpifrance led theoperation via the InnoBio fund. The InnoBio fund has taken anequity stake in the company with an investment of €3.5 million.Alizé Pharma SAS’ historical investors Octalfa, Sham InnovationSanté, CEMA and Tab Consulting have also contributed. Sinceits creation in 2007, AlizéPharma SAS has raised a total of €10 million.AZP-531 is a stabilised analogue of unacylated ghrelin, agastro-intestinal hormone.It is under development by Alizé Pharma SAS for use in various metabolic and cardiovascular indications.Thierry Abribat, manager of TAB Consulting and president of Alizé Pharma says, “This injection marks afundamental step forward. It will help generate the first efficacy data for AZP-531 in the target indications.”Exova appoints Alison Clayton as European GMExova, the global testing, calibration and advisoryservices provider, has appointed Dr Alison Clayton asgeneral manager of its European pharmaceuticalbusiness.With a career spanning more than twenty years inpharmaceuticals, Alison joins Exova from Quintileswhere she was most recently in the position of globalhead of project services for the Central Laboratorybusiness, responsible for managing global teams,customer account management and generating andimplementing both operational and strategic plans.In her new role, Alison will be responsible forExova’s Edinburgh and Camberley laboratories,utilising her operational experience, technicalknowledge and solid understanding of the regulatory framework in which Exova’s customers operate.Phil Coles, director of health sciences, Europe at Exova, says, “Alison has built a strong career inpharmaceuticals and her extensive experience in operations management and knowledge of the industry makesher a valuable asset to our customers.”Curie-Cancer and Inventiva announce epigeneticspartnershipCurie-Cancer, the body responsible fordeveloping Institut Curie’s industry partnershipactivities, and Inventiva have launched the Epicureproject, which has just received financial backingfrom France’s national research agency, the ANR.The Epicure project focuses on two novelepigenetic targets implicated in immunomodulation.It aims to confirm their therapeutic potential for thetreatment of cancers such as breast cancer, ovariancancer and melanoma, as well as some respiratorydiseases. It also aims to identify molecules that arecapable of regulating the activity of the targets and are therefore likely to become active drugs for the treatment ofthese diseases.The funding provided by the ANR covers a period of four years.34-37:Layout 1 22/9/14 09:42 Page 2PHARMA BUSINESS INTERNATIONAL36Pharma Business International www.pbiforum.netThe knowledge base amongpharmaceutical companies is enormous,so collaborations that make the most ofthe skills and expertise of a number ofcompanies can have a huge impact onthe sector. There are certainly numerousexamples of some of the sector’s majornames launching extensive projectsalongside their colleagues and peers.The ability to merge the specialistareas of two or more individualcompanies ensure they can punch wellabove their weight on a global scale. Inclinical trials, for example, the Swedishcompanies CTC Clinical Trial Consultantsand Recipharm PharmaceuticalBusinesses and consumers alike benefitfrom increased collaboration in the industryLet’s worktogetherDevelopment have entered into acollaboration to offer a complete set ofpackages for Phase I studies includingdevelopment and manufacture of clinicaltrial material.Bengt Dahlström, CEO of CTC ClinicalTrial, says, “This systematic integratedapproach will help our clients to shortenproject time-lines and at the same timeobtain more information on the desirableproperties of the drug formulation.Adaptive design is a key element ingetting more information from each studyand modifying the design based on thedata obtained all within a single protocol.”In many cases, collaboration allowsR&D to be commercialised under theauspices of a major manufacturer. One ofthe latest examples is at Adaptimmune,the leading biotechnology companydeveloping TCR engineered T-cells totreat cancer, which has entered into astrategic collaboration and licensingagreement with GlaxoSmithKline for thedevelopment and commercialisation of itslead clinical cancer programme.Using its unique T-cell receptorengineering technology, Adaptimmunehas created TCRs which are deployed totarget the cancer testis antigen NY-ESO-1and other targets. The company’s trials inthe NY-ESO-1 programme in multiple34-37:Layout 1 22/9/14 09:42 Page 3Pharma Business International 37www.pbiforum.netPHARMA BUSINESS INTERNATIONALdrugs to other companies outside thescope of the set of GPCRs selected byXOMA.As research and development is a vitalaspect of the pharmaceutical sector,there are certainly numerous benefits tobe achieved by working alongsidespecialists in the field, rather thanwasting efforts on replicating existingoperations. d3 Medicine LLC, the expertbiopharmaceutical strategic advisorycompany, and Viroclinics Biosciences,the virology service organisation, havesigned a non-exclusive Memorandum ofUnderstanding to providebiopharmaceutical customers with anintegrated solution to accelerate thepreclinical and clinical development ofdrugs, biologicals, vaccines anddiagnostics targeting viral infectiousdiseases.The alliance leverages the strengths ofthe two companies and will offer servicesthat enable customers to acceleratevirological investigational agents, throughpreclinical and clinical development, tomarket launch. Viroclinics Bioscienceswill provide a range of preclinical andclinical diagnostic services, includinghigh throughput serology, virology andmolecular assays, phenotyping andgenotyping in both translational studiesand phase I-IV clinical studies, andclinical trial logistics services.d3 Medicine will formulate integrateddevelopment, clinical pharmacology andtranslational medicine strategies to fast-track preclinical development and definecustomised pharmacometric andquantitative pharmacological approachesto improve decision making and accelerateclinical and regulatory development.As Dr Craig Rayner, CEO and co-Founder of d3 Medicine, points out,“Biopharmaceutical companies now canturn to d3 Medicine and ViroclinicsBiosciences to develop and implementtheir preclinical, clinical and regulatorystrategies when developing therapeutics,vaccines and diagnostics for viralinfectious diseases.”Collaborative efforts such as these arebringing together already successfulcompanies to create an unbeatablealliance to allow them to move forwardfaster and more effectively than everbefore.PHOTO: SHUTTERSTOCK.COM/PRESSMASTERmyeloma, melanoma, sarcoma andovarian cancer in the US are generatingencouraging results, with European trialsset to commence shortly, with numerousfollow-on programmes.Under the terms of the agreement,Adaptimmune will co-develop its NY-ESO-1 clinical programme andassociated manufacturing optimisationwork together with GSK. GSK will havean option on the NY-ESO-1 programmethrough clinical proof of concept, whichis anticipated during 2016, and will alsoassume full responsibility for theprogramme. The companies will also co-develop other TCR target programmesand collaborate on further optimisation ofengineered TCR products.According to the development plan, thisdeal could yield payments in excess of$350 million to Adaptimmune over thenext seven years, with significantadditional development andcommercialisation payments insubsequent years if GSK exercises all itsoptions and milestones continue to bemet. In addition, Adaptimmune would alsoreceive tiered royalties ranging from singleto double digits on net sales. James Noble, Chief Executive Officer ofAdaptimmune, says, “We’re delighted tocollaborate with GSK, a leadingpharmaceutical company which has madea strategic commitment to immuno-oncology. Its substantial development andmanufacturing expertise in key areas willbe invaluable as we work together toaccelerate the development of ourprogrammes and bring potentiallybreakthrough cancer therapies to patients.”Axel Hoos, Vice President of OncologyR&D and Head of Immuno-Oncology ofGSK, says, “We believe thatAdaptimmune’s T-cell receptorengineering technology will be synergisticwith the growing immuno-oncologyportfolio of GSK and leverage our existingexpertise in autologous cell gene therapy.Together this combination of capabilitiesoffers an opportunity for significantprogress in the use of the body’s immunesystem to fight cancer.”Another example of this in practicecomes from Domain Therapeutics, whichspecialises in new drug candidatestargeting G protein-coupled receptors,and has entered into a multi-stepcollaboration with XOMA Corporation.XOMA focuses its research on allostericmodulation which offers opportunities fornew classes of therapeutic antibodies totreat a wide range of human diseases.Domain Therapeutics operates DTect-All,a platform that has successfullydiscovered small molecule allostericmodulators for a wide range of GPCRs.Domain Therapeutics and XOMA willjointly evaluate the robustness of DTect-Allto identify allosteric modulator antibodies ofa first target. If it’s successful, the partnersmay further collaborate on other GPCRs.Domain will have the right to offer its DTect-All platform to discover antibody-based34-37:Layout 1 22/9/14 09:42 Page 438 Food & Drink Internationalwww.fdiforum.netGULFOOD MANUFACTURINGAmid steady domestic and regionalgrowth, the sector-specific spin-off ofGulfood will debut as the Middle East,Africa and South East Asia’s biggest-evertrade show launch. With a host of globalfood manufacturers, suppliers and serviceproviders requesting exhibition space,organiser DWTC is adding new halls tocater for international demand.More than a thousand internationalsuppliers have committed to the specialistshow, which is expected to gather morethan ten thousand regional and globaltrade visitors, as well another 1500delegates who will share the latestindustry insights in a number ofconferences and technical workshops.Trixie LohMirmand of DWTC says,“The Middle East is rightly viewed as akey growth territory for the global foodprocessing, packaging and manufacturingsectors. Gulfood Manufacturing will giveinternational equipment, logistics and coldchain suppliers a tailored investmentplatform to gain an operational footholdin one of the world’s fastest growingmarkets.packaged foods already accounting formore than 50% of the GCC’s total foodmarket, ProPack Middle East andIngredients Middle East will strengthenthe UAE’s position as the region’s drivingforce in both lucrative sectors.Gulfood Manufacturing will also host aFood Safety Conference highlightingissues related to regional food safety, witha host of internationally-acclaimedspeakers and key industry figures. Gulfood Manufacturing is heldfrom 9th to 11th November atDWTC, and for moreinformation, visitwww.gulfoodmanufacturing.com Gulfood Manufacturing is meeting unprecedented market demand for the region’s manufacturing,processing, packaging and ingredients sectors on 9th to 11th November at Dubai World Trade CentreThe region’s biggestever trade show“Internationally, the sector is seeingmulti-billion dollar investments andGulfood Manufacturing will helpfacilitate and accelerate regionaldevelopment. The fact the show is soldout five months ahead of its launchspeaks volumes about how internationalsuppliers, producers and manufacturersin various segmented industry sectorsview the burgeoning regional market. Wehave listened to our customers and havecommitted to extending the debut show’scapacity.”With the logistics industry a majorcontributor to the country’s economicdevelopment, Food Logistics Middle Eastwill highlight key trends affecting theglobal sector, such asmaterials handling,transport andcommercial vehicles,IT and technology,warehousing andoperators, facilitatorsand service providers. Elsewhere, withprocessed and38-39:Layout 1 23/9/14 08:44 Page 1Wire Belt CompanyAt Gulfood Manufacturing, Wire BeltCompany will display its range of metalconveyor belting and conveyor systems.Wire Belt Company has a long history ofproducing steel mesh belting and conveyorsystems providing customised open mesh,hygienic, safe and efficient conveyorsolutions. Manufacturing a belting range thatalso includes Eye-Flex, CompactGrid,Honeycomb and Spiral Woven Mesh, Wire Belt has the product to offer improved efficiency in manyapplications.They offer many styles and specifications of open mesh conveyor belt to suit any application, along withtheir latest innovation Versa-Link, a durable and open mesh belt available for light to medium dutyapplications. Versa-Link’s many unique features make it the belt you need on your conveyor.At Gulfood Manufacturing, Wire Belt’s stand will have a selection of belting and conveyor products on display.Tel; +44 (0) 1795 421771 Email: wthrower@wirebelt.co.uk www.wirebelt.co.ukStand S-D38Food & Drink International 39www.fdiforum.netGULFOOD MANUFACTURINGEmsland GroupAs Germany’s largest producer ofpotato starch and a global leader inmanufacturing refined starchproducts, proteins and fibres, as wellas potato flakes and granules,Emsland Group creates innovativeproducts for the whole food industry.Besides its worldwide establishedsolutions the company is presentingphysically-treated dehydratedpotatoes (Embalance) as well asclean label starches and flakes (Empure) at this years’ Gulfood Manufacturing / IngredientsMiddle East. Furthermore Emsland Group offers a wide range of coating systems. Besidestempura batters and clear coatings also breadings and seasoning coatings are available.‘Using nature to create’ is the guiding principle that characterises Emsland Group’scompany philosophy. The company offers solutions for trends such as clean label, gluten-free,fibre enriched, sustainability, acrylamide reduction, vegan as well as non-GMO and natural. Tel. +49 (0) 5943810 Fax +49 (0)594381205 Email: info@emsland-group.deStand S1-E33A.M.P-RoseEstablished over 35 years ago, A.M.P-Rose is one ofthe world’s leading suppliers of new, used, and rebuiltmachines to the chocolate and confectionery industries.This year at the Gulfood Manufacturing exhibition;A.M.P-Rose will be showcasing their brand newNeapolitan wrapping machine. It is an adjustable highspeed automatic Neapolitan wrapping machine for squareand rectangle tablets. The machine can be supplied as ahand fed machine, or with an automatic feeding system. The wrapping machine can perform single or doublewrap, with the inner wrap from reel, and outer wrap fromstack. As well as band wrapping the chocolate, theNeapolitan machine can also overwrap it.This affordable machine is designed for chocolatemanufacturers and contract packers alike. Tel: +44 (0) 1427 611 969 Email: info@amp-rose.comwww.amp-rose.comStand S-E39Russell FinexRussell Finex, worldwideleaders in fine meshseparation, will showcasetheir innovative range ofvibratory screeners andself-cleaning liquid filtersat Gulfood Manufacturing.With eighty years ofexperience serving customersin a variety of industries incountries all over the world,Russell Finex will be fully equippedto share their knowledge and expertisewith stand visitors.Providing custom built solutions to suit customers’ unique requirements,the following range of machines will be on display...Grading and screening machines – vibratory screeners and gradingseparators wet and dry applications to enhance product quality andincrease productivity.Ultrasonic screen deblinding systems – eliminates mesh blinding andblocking, allowing sieving on finer meshes and increased screening capacityIndustrial liquid filters – fully enclosed self-cleaning filters to removecontamination from liquids.Visit Russell Finex at Gulfood Manufacturing to see how they can helpyou improve your food manufacturing processes.Tel: +44 (0)20 8818 2000 www.russellfinex.comStand S-E71OYSTARDesigned for thefilling and sealing ofpre-formed cups,the new developedM-FS 30 Filling andSealing Machinefrom OYSTARHamba andOYSTAR Gastifeatures a chainlessdrive conceptallowing forautomated format changes in less than twenty minutes.This significantly improves equipment availability for production and,ultimately, OEE as well by making it profitable to produce even variablepackaging formats. During format change, a mobile trolley storage unit isattached to the machine. Maintenance costs for the M-FS 30 are reduced because there is no needto replace the transport chain or carry out any of the adjustment workneeded for chain stretch. The machine can be equipped with up to threedosing systems and it can process up to 30,000 cups per hour across amaximum of 12 lanes. The machine operates without lubricant and usingoptional UV-C disinfection for cups and lids makes it ideal for hygienicproduction applications.www.oystar-group.comStand Z-B9638-39:Layout 1 23/9/14 08:44 Page 2Next >